Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

키워드

참고문헌 (19)

1. Rinella ME, "Nonalcoholic fatty liver disease : a systematic review", JAMA, 313, pp.2263~2273 (2015)
2. Newsome PN, "FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
3. Harrison SA, "A blood-based biomarker panel(NIS4)for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.970~985 (2020)
4. Angulo P, "Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?", Hepatology, 51, pp.373~375 (2010)
5. Angulo P, "Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 145, pp.782~789 (2013)
6. Harrison SA, "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease", Gut, 57, pp.1441~1447 (2008)
7. Boursier J, "An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards", J Hepatol, 62, pp.807~815 (2015)
8. Alkhouri N, "Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD", Gastroenterol Hepatol(N Y), 8, pp.661~668 (2012)
9. Tina Reinson, "Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future", Clinical and Molecular Hepatology, 29, pp.157~170 (2023), 대한간학회
10. Sarvestany SS, "Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis : a retrospective cohort study", Lancet Digit Health, 4, pp.e188~e199 (2022)
11. Yilmaz Y, "Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease : a registry-based study", Aliment Pharmacol Ther, 57, pp.215~223 (2023)
12. Anstee QM, "Impact of non-invasive biomarkers on hepatology practice : Past, present and future", J Hepatol, 76, pp.1362~1378 (2022)
13. Ajmera VH, "Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease", Hepatology, 71, pp.849~860 (2020)
14. Harrington C, "Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis", Hepatology, 76, pp.1862~1879 (2022)
15. Ratziu V, "Breakthroughs in therapies for NASH and remaining challenges", J Hepatol, 76, pp.1263~1278 (2022)
16. Reiberger T, "The Baveno VII concept of cirrhosis recompensation", Dig Liver Dis (2023)[DOI]
17. Noureddin N, "Driving nonalcoholic steatohepatitis forward using the FibroScan aspartate aminotransferase score, but obey the traffic lights", Hepatology, 72, pp.2228~2230 (2020)
18. Jung J, "MRE combined with FIB-4(MEFIB)index in detection of candidates for pharmacological treatment of NASH-related fibrosis", Gut, 70, pp.1946~1953 (2021)
19. Kim BK, "Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD", J Hepatol, 77, pp.1482~1490 (2022)